Last reviewed · How we verify
Pandemic influenza vaccine GSK2340272A — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Pandemic influenza vaccine GSK2340272A (Pandemic influenza vaccine GSK2340272A) — GlaxoSmithKline. This vaccine induces an immune response against pandemic influenza.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pandemic influenza vaccine GSK2340272A TARGET | Pandemic influenza vaccine GSK2340272A | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pandemic influenza vaccine GSK2340272A CI watch — RSS
- Pandemic influenza vaccine GSK2340272A CI watch — Atom
- Pandemic influenza vaccine GSK2340272A CI watch — JSON
- Pandemic influenza vaccine GSK2340272A alone — RSS
Cite this brief
Drug Landscape (2026). Pandemic influenza vaccine GSK2340272A — Competitive Intelligence Brief. https://druglandscape.com/ci/pandemic-influenza-vaccine-gsk2340272a. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab